The accuracy of provider diagnosed diabetes type in youth compared to an etiologic criteria in the SEARCH for Diabetes in Youth Study.


Journal

Pediatric diabetes
ISSN: 1399-5448
Titre abrégé: Pediatr Diabetes
Pays: Denmark
ID NLM: 100939345

Informations de publication

Date de publication:
12 2020
Historique:
received: 29 06 2020
revised: 10 09 2020
accepted: 16 09 2020
pubmed: 28 9 2020
medline: 13 7 2021
entrez: 27 9 2020
Statut: ppublish

Résumé

Although surveillance for diabetes in youth relies on provider-assigned diabetes type from medical records, its accuracy compared to an etiologic definition is unknown. Using the SEARCH for Diabetes in Youth Registry, we evaluated the validity and accuracy of provider-assigned diabetes type abstracted from medical records against etiologic criteria that included the presence of diabetes autoantibodies (DAA) and insulin sensitivity. Youth who were incident for diabetes in 2002-2006, 2008, or 2012 and had complete data on key analysis variables were included (n = 4001, 85% provider diagnosed type 1). The etiologic definition for type 1 diabetes was ≥1 positive DAA titer(s) or negative DAA titers in the presence of insulin sensitivity and for type 2 diabetes was negative DAA titers in the presence of insulin resistance. Provider diagnosed diabetes type correctly agreed with the etiologic definition of type for 89.9% of cases. Provider diagnosed type 1 diabetes was 96.9% sensitive, 82.8% specific, had a positive predictive value (PPV) of 97.0% and a negative predictive value (NPV) of 82.7%. Provider diagnosed type 2 diabetes was 82.8% sensitive, 96.9% specific, had a PPV and NPV of 82.7% and 97.0%, respectively. Provider diagnosis of diabetes type agreed with etiologic criteria for 90% of the cases. While the sensitivity and PPV were high for youth with type 1 diabetes, the lower sensitivity and PPV for type 2 diabetes highlights the value of DAA testing and assessment of insulin sensitivity status to ensure estimates are not biased by misclassification.

Sections du résumé

BACKGROUND
Although surveillance for diabetes in youth relies on provider-assigned diabetes type from medical records, its accuracy compared to an etiologic definition is unknown.
METHODS
Using the SEARCH for Diabetes in Youth Registry, we evaluated the validity and accuracy of provider-assigned diabetes type abstracted from medical records against etiologic criteria that included the presence of diabetes autoantibodies (DAA) and insulin sensitivity. Youth who were incident for diabetes in 2002-2006, 2008, or 2012 and had complete data on key analysis variables were included (n = 4001, 85% provider diagnosed type 1). The etiologic definition for type 1 diabetes was ≥1 positive DAA titer(s) or negative DAA titers in the presence of insulin sensitivity and for type 2 diabetes was negative DAA titers in the presence of insulin resistance.
RESULTS
Provider diagnosed diabetes type correctly agreed with the etiologic definition of type for 89.9% of cases. Provider diagnosed type 1 diabetes was 96.9% sensitive, 82.8% specific, had a positive predictive value (PPV) of 97.0% and a negative predictive value (NPV) of 82.7%. Provider diagnosed type 2 diabetes was 82.8% sensitive, 96.9% specific, had a PPV and NPV of 82.7% and 97.0%, respectively.
CONCLUSION
Provider diagnosis of diabetes type agreed with etiologic criteria for 90% of the cases. While the sensitivity and PPV were high for youth with type 1 diabetes, the lower sensitivity and PPV for type 2 diabetes highlights the value of DAA testing and assessment of insulin sensitivity status to ensure estimates are not biased by misclassification.

Identifiants

pubmed: 32981196
doi: 10.1111/pedi.13126
pmc: PMC7819667
mid: NIHMS1658460
doi:

Types de publication

Comparative Study Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1403-1411

Subventions

Organisme : NCCDPHP CDC HHS
ID : U18 DP006134
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000154
Pays : United States
Organisme : CDC HHS
ID : U48/CCU819241-3
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U01 DP000244
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000062
Pays : United States
Organisme : ACL HHS
ID : U18DP006134
Pays : United States
Organisme : CDC HHS
ID : PA 00097
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001425
Pays : United States
Organisme : CDC HHS
ID : U18DP006139
Pays : United States
Organisme : CDC HHS
ID : U18DP006138
Pays : United States
Organisme : CDC HHS
ID : U48/CCU519239
Pays : United States
Organisme : NIDDK NIH HHS
ID : 1UC4DK108173
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK057516
Pays : United States
Organisme : ACL HHS
ID : U18DP006139
Pays : United States
Organisme : NIDDK NIH HHS
ID : UC4 DK108173
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U01 DP000247
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U18 DP006131
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U18 DP002710
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR00423
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U18 DP006138
Pays : United States
Organisme : CDC HHS
ID : 200-2010-35 171
Pays : United States
Organisme : CDC HHS
ID : U48/CCU919219
Pays : United States
Organisme : ACL HHS
ID : U18DP006138
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U18 DP002714
Pays : United States
Organisme : CDC HHS
ID : U18DP006134
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 Tr001450
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U01 DP000248
Pays : United States
Organisme : CDC HHS
ID : U18DP002714
Pays : United States
Organisme : CDC HHS
ID : U48/CCU419249
Pays : United States
Organisme : CDC HHS
ID : 1U18DP002709
Pays : United States
Organisme : CDC HHS
ID : U58/CCU019235-4
Pays : United States
Organisme : CDC HHS
ID : U18DP002710-01
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U18 DP006136
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U18 DP002709
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U18 DP006133
Pays : United States
Organisme : CDC HHS
ID : U18DP006136
Pays : United States
Organisme : ACL HHS
ID : U18DP006131
Pays : United States
Organisme : CDC HHS
ID : DP-10-001
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U18 DP006139
Pays : United States
Organisme : CDC HHS
ID : U18DP006133
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000077
Pays : United States
Organisme : CDC HHS
ID : DP-05-069
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK127208
Pays : United States
Organisme : CDC HHS
ID : 1U18DP006131
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000423
Pays : United States
Organisme : ACL HHS
ID : U18DP006136
Pays : United States
Organisme : CDC HHS
ID : U18DP000247-06A1
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U01 DP000250
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U01 DP000246
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U01 DP000254
Pays : United States
Organisme : ACL HHS
ID : U18DP006133
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U18 DP002708
Pays : United States
Organisme : HSRD VA
ID : HIR 10-001
Pays : United States
Organisme : CDC HHS
ID : U18DP002708
Pays : United States

Informations de copyright

© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Pediatrics. 2014 Apr;133(4):e938-45
pubmed: 24685959
Am J Epidemiol. 2014 Jan 1;179(1):27-38
pubmed: 24100956
BMJ Open Diabetes Res Care. 2019 Feb 16;7(1):e000547
pubmed: 30899525
Diabetes Care. 2002 Aug;25(8):1326-30
pubmed: 12145229
Diabetes Care. 2013 Apr;36(4):914-21
pubmed: 23193215
JAMA. 2014 May 7;311(17):1778-86
pubmed: 24794371
Contemp Clin Trials. 2008 Nov;29(6):829-36
pubmed: 18573350
Pediatr Diabetes. 2012 May;13(3):229-34
pubmed: 21771232
JAMA. 2017 Feb 28;317(8):825-835
pubmed: 28245334
Pediatr Diabetes. 2020 Jun 19;:
pubmed: 32562358
Vital Health Stat 2. 2003 Sep;(135):1-55
pubmed: 14556588
Diabetes Care. 2011 Jul;34(7):1628-33
pubmed: 21636800
Int J Obes (Lond). 2009 Jul;33(7):716-26
pubmed: 19506563
Diabetes. 1998 May;47(5):733-42
pubmed: 9588444
N Engl J Med. 2017 Jul 20;377(3):301
pubmed: 28723318
Pediatr Diabetes. 2014 Dec;15(8):573-84
pubmed: 24913103
Diabetes Care. 2014 Dec;37(12):3336-44
pubmed: 25414389
J Clin Endocrinol Metab. 2010 Jul;95(7):3360-7
pubmed: 20444913
J Am Med Inform Assoc. 2016 Nov;23(6):1060-1067
pubmed: 27107449
J Pediatr. 2013 Feb;162(2):297-301
pubmed: 22921593
JAMA. 2018 Apr 24;319(16):1723-1725
pubmed: 29570750
J Pediatr. 2004 Oct;145(4):439-44
pubmed: 15480363
Diabetes Care. 2006 Sep;29(9):2130-6
pubmed: 16936167
Diabetologia. 2011 Jan;54(1):78-86
pubmed: 20886205
Diabetes Care. 2010 Jan;33 Suppl 1:S62-9
pubmed: 20042775
Diabet Med. 1997 Nov;14(11):989-91
pubmed: 9400927
Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17040-5
pubmed: 17942684
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571

Auteurs

Tessa L Crume (TL)

Department of Epidemiology, Colorado School of Public Health, University of Colorado, Lifecourse Epidemiology of Adiposity and Diabetes (LEAD Center) Anschutz Medical Campus, Denver, Colorado, USA.

Richard F Hamman (RF)

Department of Epidemiology, Colorado School of Public Health, University of Colorado, Lifecourse Epidemiology of Adiposity and Diabetes (LEAD Center) Anschutz Medical Campus, Denver, Colorado, USA.

Scott Isom (S)

Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.

Jasmin Divers (J)

Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.

Elizabeth J Mayer-Davis (EJ)

School of Public Health and School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Angela D Liese (AD)

Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, South Carolina, USA.

Sharon Saydah (S)

Division of Diabetes Translation, Centers for Disease Control and Prevention, Hyattsville, Maryland, USA.

Jean M Lawrence (JM)

Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.

Catherine Pihoker (C)

Department of Pediatric Endocrinology, Children's Hospital & Regional Medical Center, Seattle, Washington, USA.

Dana Dabelea (D)

Department of Epidemiology, Colorado School of Public Health, University of Colorado, Lifecourse Epidemiology of Adiposity and Diabetes (LEAD Center) Anschutz Medical Campus, Denver, Colorado, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH